Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
April 30, 2014 at 16:26 PM EDT
Theravance, Inc. (NASDAQ: THRX) today announced positive results from a Phase 2 study of TD-9855, an investigational norepinephrine and ...
